The DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.
The Uniqueness of Albumin as a Carrier in Nanodrug Delivery
Open accessAbstract
, thus improving their pharmacokinetic properties. Finally, albumin can interact with receptors overexpressed in many diseased tissues and cells, providing a unique feature for active targeting of the disease site without the addition of specific ligands to the nanocarrier. For this reason, albumin, characterized by an extended serum half-life of around 19 days, has the potential of promoting half-life extension and targeted delivery of drugs. Therefore, this article focuses on the importance of albumin as a nanodrug delivery carrier for hydrophobic drugs, taking advantage of the passive as well as active targeting potential of this nanocarrier. Particular attention is paid to the breakthrough NAB-Technology, with emphasis on the advantages of Nab-Paclitaxel (Abraxane), compared to the solvent-based formulations of Paclitaxel, i.e., CrEL-paclitaxel (Taxol) in a clinical setting. Finally, the role of albumin in carrying anticancer compounds is depicted, with a particular focus on the albumin-based formulations that are currently undergoing clinical trials. The article sheds light on the power of an endogenous substance, such as albumin, as a drug delivery system, signifies the importance of the drug vehicle in drug performance in the biological systems, and highlights the possible future trends in the use of this drug delivery system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Nanoparticle PEGylation for Imaging and Therapy
Jokerst, J. V., Lobovkina, T., Zare, R. N., & Gambhir, S. S. (2011) · Nanomedicine · doi:10.2217/nnm.11.19 · Cited by 2,046
Human serum albumin: From bench to bedside
Fanali, G., di Masi, A., Trezza, V., Marino, M., Fasano, M., & Ascenzi, P. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.12.002 · Cited by 1,931
The entry of nanoparticles into solid tumours
Sindhwani, S., Syed, A. M., Ngai, J., Kingston, B. R., Maiorino, L., Rothschild, J., MacMillan, P., Zhang, Y., Rajesh, N. U., Hoang, T., et al. (2020) · Nature Materials · doi:10.1038/s41563-019-0566-2 · Cited by 1,732
The Characterization of Two Specific Drug Binding Sites on Human Serum Albumin
SUDLOW, G., BIRKETT, D. J., & WADE, D. N. (1975) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10691-3 · Cited by 1,725
Doxorubicin pathways: pharmacodynamics and adverse effects
Thorn, C. F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833ffb56 · Cited by 1,648
Albumin-based nanoparticles as potential controlled release drug delivery systems
Elzoghby, A. O., Samy, W. M., & Elgindy, N. A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.031 · Cited by 1,520
Nanoparticle uptake: The phagocyte problem
Gustafson, H. H., Holt-Casper, D., Grainger, D. W., & Ghandehari, H. (2015) · Nano Today · doi:10.1016/j.nantod.2015.06.006 · Cited by 1,411
Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1634 · Cited by 1,175
Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
Nakamura, Y., Mochida, A., Choyke, P. L., & Kobayashi, H. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00437 · Cited by 1,101
The role of albumin in critical illness
Nicholson, J. P., Wolmarans, M. R., & Park, G. R. (2000) · British Journal of Anaesthesia · doi:10.1093/bja/85.4.599 · Cited by 939
Lombardo, D., Kiselev, M. A., & Caccamo, M. T. (2019) · Journal of Nanomaterials · doi:10.1155/2019/3702518 · Cited by 864
Impact of albumin on drug delivery — New applications on the horizon
Elsadek, B., & Kratz, F. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.069 · Cited by 832
Levitt, D., & Levitt, M. (2016) · International Journal of General Medicine · doi:10.2147/ijgm.s102819 · Cited by 763
Optimization of the preparation process for human serum albumin (HSA) nanoparticles
Langer, K., Balthasar, S., Vogel, V., Dinauer, N., von Briesen, H., & Schubert, D. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00134-0 · Cited by 757
Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Zhang, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5848 · Cited by 756
Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems
Yoo, J., Park, C., Yi, G., Lee, D., & Koo, H. (2019) · Cancers · doi:10.3390/cancers11050640 · Cited by 726
Albumin-bound paclitaxel: a next-generation taxane
Gradishar, W. J. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1041 · Cited by 712
Ibrahim, N. K., Desai, N. P., Legha, S. S., Soon‐Shiong, P., Theriault, R. L., Rivera, E., Esmaeli, B., Ring, S. E., Bedikian, A. Y., Hortobágyi, G. N., et al. (2002) · PubMed · Cited by 705
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Tomao, S. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s3061 · Cited by 695
Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA
Belliveau, N. M., Huft, J., Lin, P. J., Chen, S., Leung, A. K., Leaver, T. J., Wild, A. W., Lee, J. B., Taylor, R. J., Tam, Y. K., et al. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.28 · Cited by 685
Albumin-based drug delivery: harnessing nature to cure disease
Larsen, M. T., Kuhlmann, M., Hvam, M. L., & Howard, K. A. (2016) · Molecular and Cellular Therapies · doi:10.1186/s40591-016-0048-8 · Cited by 683
Protein corona: a new approach for nanomedicine design
Nguyen, V. H., & Lee, B.-J. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s129300 · Cited by 638
Harnessing albumin as a carrier for cancer therapies
Hoogenboezem, E. N., & Duvall, C. L. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.011 · Cited by 610
Human serum albumin, systemic inflammation, and cirrhosis
Arroyo, V., García-Martinez, R., & Salvatella, X. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.04.012 · Cited by 560
Ding, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557
Wang, S., Su, R., Nie, S., Sun, M., Zhang, J., Wu, D., & Moustaid-Moussa, N. (2014) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.10.002 · Cited by 531
Sparreboom, A., Scripture, C. D., Trieu, V., Williams, P. J., De, T., Yang, A., Beals, B., Figg, W. D., Hawkins, M., & Desai, N. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2291 · Cited by 504
Methotrexate an Old Drug with New Tricks
Bedoui, Y., Guillot, X., Sélambarom, J., Guiraud, P., Giry, C., Jaffar-Bandjee, M. C., Ralandison, S., & Gasque, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205023 · Cited by 471
An, F.-F., & Zhang, X.-H. (2017) · Theranostics · doi:10.7150/thno.19365 · Cited by 436
Albumin nanostructures as advanced drug delivery systems
Karimi, M., Bahrami, S., Ravari, S. B., Zangabad, P. S., Mirshekari, H., Bozorgomid, M., Shahreza, S., Sori, M., & Hamblin, M. R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1193149 · Cited by 422
Nano spray drying: A novel method for preparing protein nanoparticles for protein therapy
Lee, S. H., Heng, D., Ng, W. K., Chan, H.-K., & Tan, R. B. H. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.10.012 · Cited by 405
Park, J., Choi, Y., Chang, H., Um, W., Ryu, J. H., & Kwon, I. C. (2019) · Theranostics · doi:10.7150/thno.37198 · Cited by 382
Structure and properties of ovalbumin
Huntington, J. A., & Stein, P. E. (2001) · Journal of Chromatography B: Biomedical Sciences and Applications · doi:10.1016/s0378-4347(01)00108-6 · Cited by 380
Beyond antigens and adjuvants: formulating future vaccines
Moyer, T. J., Zmolek, A. C., & Irvine, D. J. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81083 · Cited by 374
Preformed albumin corona, a protective coating for nanoparticles based drug delivery system
Peng, Q., Zhang, S., Yang, Q., Zhang, T., Wei, X.-Q., Jiang, L., Zhang, C.-L., Chen, Q.-M., Zhang, Z.-R., & Lin, Y.-F. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.102 · Cited by 366
Bertucci, C., & Domenici, E. (2002) · Current Medicinal Chemistry · doi:10.2174/0929867023369673 · Cited by 354
Questioning the use of PEGylation for drug delivery
Verhoef, J. J. F., & Anchordoquy, T. J. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0176-5 · Cited by 342
A clinical update of using albumin as a drug vehicle — A commentary
Kratz, F. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.013 · Cited by 334
Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy
Zhu, G., Lynn, G. M., Jacobson, O., Chen, K., Liu, Y., Zhang, H., Ma, Y., Zhang, F., Tian, R., Ni, Q., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02191-y · Cited by 315
Personalized protein corona on nanoparticles and its clinical implications
Corbo, C., Molinaro, R., Tabatabaei, M., Farokhzad, O. C., & Mahmoudi, M. (2017) · Biomaterials Science · doi:10.1039/c6bm00921b · Cited by 308
Personalized protein coronas: a “key” factor at the nanobiointerface
Hajipour, M. J., Laurent, S., Aghaie, A., Rezaee, F., & Mahmoudi, M. (2014) · Biomaterials Science · doi:10.1039/c4bm00131a · Cited by 307
Sand, K. M. K., Bern, M., Nilsen, J., Noordzij, H. T., Sandlie, I., & Andersen, J. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00682 · Cited by 304
Albumin Binding to FcRn: Distinct from the FcRn−IgG Interaction
Chaudhury, C., Brooks, C. L., Carter, D. C., Robinson, J. M., & Anderson, C. L. (2006) · Biochemistry · doi:10.1021/bi052628y · Cited by 290
Species Differences of Serum Albumins: I. Drug Binding Sites
Kosa, T., Maruyama, T., & Otagiri, M. (1997) · Pharmaceutical Research · doi:10.1023/a:1012138604016 · Cited by 274
Zu (2010) · International Journal of Nanomedicine · doi:10.2147/ijn.s12918 · Cited by 272
Ibrahim, N. K., Samuels, B., Page, R., Doval, D., Patel, K. M., Rao, S. C., Nair, M. K., Bhar, P., Desai, N., & Hortobagyi, G. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.013 · Cited by 267
Personalized disease-specific protein corona influences the therapeutic impact of graphene oxide
Hajipour, M. J., Raheb, J., Akhavan, O., Arjmand, S., Mashinchian, O., Rahman, M., Abdolahad, M., Serpooshan, V., Laurent, S., & Mahmoudi, M. (2015) · Nanoscale · doi:10.1039/c5nr00520e · Cited by 256
A simple improved desolvation method for the rapid preparation of albumin nanoparticles
Jahanban-Esfahlan, A., Dastmalchi, S., & Davaran, S. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.05.032 · Cited by 254
Microfluidic-assisted fabrication of carriers for controlled drug delivery
Liu, D., Zhang, H., Fontana, F., Hirvonen, J. T., & Santos, H. A. (2017) · Lab on a Chip · doi:10.1039/c7lc00242d · Cited by 254
Recent Advances in Novel Drug Carrier Systems
(2012) · InTech eBooks · doi:10.5772/2889 · Cited by 247
Tailoring the component of protein corona via simple chemistry
Lu, X., Xu, P., Ding, H.-M., Yu, Y.-S., Huo, D., & Ma, Y.-Q. (2019) · Nature Communications · doi:10.1038/s41467-019-12470-5 · Cited by 246
Advances in Delivery Systems for Doxorubicin
Zhao, N., C Woodle, M., & Mixson, A. J. (2018) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000519 · Cited by 243
Engineering of a femtomolar affinity binding protein to human serum albumin
Jonsson, A., Dogan, J., Herne, N., Abrahmsen, L., & Nygren, P.-A. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzn028 · Cited by 242
Bae, S., Ma, K., Kim, T. H., Lee, E. S., Oh, K. T., Park, E.-S., Lee, K. C., & Youn, Y. S. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.050 · Cited by 236
Targeting of albumin-embedded paclitaxel nanoparticles to tumors
Karmali, P. P., Kotamraju, V. R., Kastantin, M., Black, M., Missirlis, D., Tirrell, M., & Ruoslahti, E. (2009) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2008.07.007 · Cited by 234
New Insights About Albumin and Liver Disease
Carvalho, J. R., & Machado, M. V. (2018) · Annals of Hepatology · doi:10.5604/01.3001.0012.0916 · Cited by 229
The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery
Bern, M., Sand, K. M. K., Nilsen, J., Sandlie, I., & Andersen, J. T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.06.006 · Cited by 217
Santagostino, E., Martinowitz, U., Lissitchkov, T., Pan-Petesch, B., Hanabusa, H., Oldenburg, J., Boggio, L., Negrier, C., Pabinger, I., von Depka Prondzinski, M., et al. (2016) · Blood · doi:10.1182/blood-2015-09-669234 · Cited by 217
Phan, H. T. M., Bartelt-Hunt, S., Rodenhausen, K. B., Schubert, M., & Bartz, J. C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0141282 · Cited by 208
Albumin corona on nanoparticles – a strategic approach in drug delivery
Mariam, J., Sivakami, S., & Dongre, P. M. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1048488 · Cited by 196
Capping gold nanoparticles with albumin to improve their biomedical properties
Bolaños, K., Kogan, M. J., & Araya, E. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s210992 · Cited by 193
Albumin-Based Nanodevices as Drug Carriers
Loureiro, A., Azóia, N. G., Gomes, A. C., & Cavaco-Paulo, A. M. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160125114900 · Cited by 187
Van Roy, M., Ververken, C., Beirnaert, E., Hoefman, S., Kolkman, J., Vierboom, M., Breedveld, E., ‘t Hart, B., Poelmans, S., Bontinck, L., et al. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0651-0 · Cited by 180
Statins and cardioprotection — More than just lipid lowering?
Ludman, A., Venugopal, V., Yellon, D. M., & Hausenloy, D. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.01.002 · Cited by 180
Zorzi, A., Linciano, S., & Angelini, A. (2019) · MedChemComm · doi:10.1039/c9md00018f · Cited by 176
A review on novel methodologies for drug nanoparticle preparation: Microfluidic approach
Shrimal, P., Jadeja, G., & Patel, S. (2020) · Chemical Engineering Research and Design · doi:10.1016/j.cherd.2019.11.031 · Cited by 175
IFN‐α subtypes: distinct biological activities in anti‐viral therapy
Gibbert, K., Schlaak, J., Yang, D., & Dittmer, U. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12010 · Cited by 174
Nanoparticle Albumin - Bound (NAB) Technology is a Promising Method for Anti-Cancer Drug Delivery
Fu, Q., Sun, J., Zhang, W., Sui, X., Yan, Z., & He, Z. (2009) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489209789206869 · Cited by 169
Synthetic nanoparticles of bovine serum albumin with entrapped salicylic acid
Bronze-Uhle, E., Costa, B. C., Ximenes, V. F., & Lisboa-Filho, P. N. (2016) · Nanotechnology, Science and Applications · doi:10.2147/nsa.s117018 · Cited by 167
Adverse Effects of Doxorubicin and Its Metabolic Product on Cardiac RyR2 and SERCA2A
Hanna, A. D., Lam, A., Tham, S., Dulhunty, A. F., & Beard, N. A. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.093849 · Cited by 163
Engineering nanoparticles to overcome barriers to immunotherapy
Toy, R., & Roy, K. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10005 · Cited by 159
Desolvation process and surface characteristics of HSA-nanoparticles
Weber, C., Kreuter, J., & Langer, K. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00420-2 · Cited by 158
DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials
Kratz, F. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.6.855 · Cited by 158
Personalized liposome–protein corona in the blood of breast, gastric and pancreatic cancer patients
Colapicchioni, V., Tilio, M., Digiacomo, L., Gambini, V., Palchetti, S., Marchini, C., Pozzi, D., Occhipinti, S., Amici, A. R. D., & Caracciolo, G. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.09.002 · Cited by 148
Kinoshita, R., Ishima, Y., Chuang, V. T. G., Nakamura, H., Fang, J. Q., Watanabe, H., Shimizu, T., Okuhira, K., Ishida, T., Maeda, H., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.06.021 · Cited by 148
Albumin nanoparticles with predictable size by desolvation procedure
von Storp, B., Engel, A., Boeker, A., Plöger, M., & Langer, K. (2012) · Journal of Microencapsulation · doi:10.3109/02652048.2011.635218 · Cited by 147
Piazzini, V., Landucci, E., D’Ambrosio, M., Fasiolo, L. T., Cinci, L., Colombo, G., Pellegrini-Giampietro, D. E., Bilia, A. R., Luceri, C., & Bergonzi, M. C. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.02.005 · Cited by 147
Ruttala, H. B., & Ko, Y. T. (2015) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2015.02.040 · Cited by 141
Baggio, L. L., Huang, Q., Cao, X., & Drucker, D. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.017 · Cited by 137
Albumin Nanovectors in Cancer Therapy and Imaging
Parodi, A., Miao, J., Soond, S. M., Rudzińska, M., & Zamyatnin, A. A. (2019) · Biomolecules · doi:10.3390/biom9060218 · Cited by 136
Optimization of PEGylation Conditions for BSA Nanoparticles Using Response Surface Methodology
Kouchakzadeh, H., Shojaosadati, S. A., Maghsoudi, A., & Vasheghani‐Farahani, E. (2010) · AAPS PharmSciTech · doi:10.1208/s12249-010-9487-8 · Cited by 135
Chen, N., Brachmann, C. B., Liu, X., Pierce, D. W., Dey, J., Kerwin, W. S., Li, Y., Zhou, S. Y., Hou, S., Carleton, M. O., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2833-5 · Cited by 130
Nanoparticle Albumin-Bound Paclitaxel (Abraxane®)
Desai, N. P. (2016) · Springer eBooks · doi:10.1007/978-981-10-2116-9_6 · Cited by 129
Methotrexate Side Effects: Review Article
Gaïes, E., & Jebabli, N. (2012) · Journal of Drug Metabolism & Toxicology · doi:10.4172/2157-7609.1000125 · Cited by 123
Fanciullino, R., Ciccolini, J., & Milano, G. A. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.06.010 · Cited by 120
Be Active or Not: the Relative Contribution of Active and Passive Tumor Targeting of Nanomaterials
Li, R., Zheng, K., Yuan, C., Chen, Z., & Huang, M. (2017) · Nanotheranostics · doi:10.7150/ntno.19380 · Cited by 118
Preparation, characterization and properties in vitro and in vivo of a paclitaxel–albumin conjugate
Dosio, F., Brusa, P., Crosasso, P., Arpicco, S., & Cattel, L. (1997) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)01656-8 · Cited by 116
Wosikowski, K., Biedermann, E., Rattel, B., Breiter, N., Jank, P., Löser, R., Jansen, G., & Peters, G. J. (2003) · PubMed · Cited by 115
Melder, R. J., Osborn, B. L., Riccobene, T. A., Kanakaraj, P., Wei, P., Chen, G., Stolow, D. T., Halpern, W., Migone, T., Wang, Q., et al. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0624-7 · Cited by 113
Human serum albumin (HSA) nanoparticles stabilized with intermolecular disulfide bonds
Wang, W., Huang, Y., Zhao, S., Shao, T., & Cheng, Y. (2013) · Chemical Communications · doi:10.1039/c3cc38397k · Cited by 108
Cucinotto, I., Fiorillo, L., Gualtieri, S., Arbitrio, M., Ciliberto, D., Staropoli, N., Grimaldi, A., Luce, A., Tassone, P., Caraglia, M., et al. (2013) · Journal of Drug Delivery · doi:10.1155/2013/905091 · Cited by 107
Aljabali, A. A. A., Bakshi, H. A., Hakkim, F. L., Haggag, Y. A., Al‐Batayneh, K., Zoubi, M. S. A., Al‐Trad, B., Nasef, M. M., Satija, S., Mehta, M., et al. (2020) · Cancers · doi:10.3390/cancers12010113 · Cited by 105
Phase I and Pharmacokinetic Study of the (6-Maleimidocaproyl)Hydrazone Derivative of Doxorubicin
Unger, C., Häring, B., Medinger, M., Drevs, J., Steinbild, S., Kratz, F., & Mross, K. B. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2776 · Cited by 104
Islam, W., Fang, J. Q., Imamura, T., Etrych, T., Šubr, V., Ulbrich, K., & Maeda, H. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0696 · Cited by 101
Haggag, Y. A., & Faheem, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00140 · Cited by 91
Hartung, G., Stehle, G., Sinn, H., Wunder, A. P., Schrenk, H. H., Heeger, S., Kränzle, M., Edler, L., Frei, E., Fiebig, H., et al. (1999) · PubMed · Cited by 88
Yi, X., Lian, X., Dong, J., Wan, Z., Xia, C., Song, X., Fu, Y. S., Gong, T., & Zhang, Z. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00536 · Cited by 87
Enhanced Biostability of Nanoparticle-Based Drug Delivery Systems by Albumin Corona
Peng, Q., Wei, X., Yang, Q., Zhang, S., Zhang, T., Shao, X., Cai, X., Zhang, Z., & Lin, Y. (2015) · Nanomedicine · doi:10.2217/nnm.14.86 · Cited by 85
Qu, N., Sun, Y., Li, Y., Hao, F., Qiu, P., Teng, L., Xie, J., & Gao, Y. H. (2019) · BioMedical Engineering OnLine · doi:10.1186/s12938-019-0624-7 · Cited by 84
Efficient Delivery of Therapeutic Agents by Using Targeted Albumin Nanoparticles
Kouchakzadeh, H., Safavi, M. S., & Shojaosadati, S. A. (2015) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2014.11.002 · Cited by 82
Li, C., Li, Y., Gao, Y., Wei, N., Zhao, X., Wang, C., Li, Y., Xiu, X., & Cui, J. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.04.010 · Cited by 81
Dy, G. K., Gupta, N., & Hatoum, H. A. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s41770 · Cited by 81
Xu, W., Zheng, X., Pang, X., Pang, Z., Zhao, J., Zhang, Z., Jiang, T., Xu, W., Zhang, Q., & Jiang, X. (2016) · Oncotarget · doi:10.18632/oncotarget.8697 · Cited by 78
Zhang, B., Wan, S., Peng, X., Zhao, M., Li, S., Pu, Y., & He, B. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00327a · Cited by 78
Bolling, C., Graefe, T., Lübbing, C., Jankevičius, F., Uktveris, S., Česas, A., Meyer‐Moldenhauer, W., Starkmann, H., Weigel, M. T., Burk, K., et al. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-8221-6 · Cited by 77
Cabazitaxel-loaded human serum albumin nanoparticles as a therapeutic agent against prostate cancer
Teng, L., Lee, R. J., Sun, Y., et al. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s105420 · Cited by 76
Li, Y., Shi, S., Ming, Y., Wang, L., Li, C., Luo, M., Li, Z., Li, B., & Chen, J. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0424-4 · Cited by 76
Vis, A. N., van der Gaast, A., van Rhijn, B., Catsburg, T., Schmidt, C., & Mickisch, G. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-001-0417-z · Cited by 75
Nanotechnology in Drug Delivery
Emeje, M. O., Ezenyi, I. C., Akpabio, E. I., & Ifianyi, S. (2012) · InTech eBooks · doi:10.5772/51384 · Cited by 74
Chen, B., He, X., Yi, X., Zhuo, R., & Cheng, S. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b03866 · Cited by 73
Aptamer-functionalized albumin-based nanoparticles for targeted drug delivery
Xu, L., He, X., Liu, B., Xu, C., Ai, S., Zhuo, R., & Cheng, S. (2018) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2018.07.008 · Cited by 73
130-nm Albumin–Bound Paclitaxel Enhances Tumor Radiocurability and Therapeutic Gain
Wiedenmann, N. E., Valdecanas, D. R., Hunter, N. R., Hyde, S. J., Buchholz, T. A., Milas, L., & Mason, K. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2534 · Cited by 71
BSA Nanoparticle Loaded Atorvastatin Calcium - A New Facet for an Old Drug
Sripriyalakshmi, S., H, A. C., Doss, C. G. P., Rajith, B., & Ravindran, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086317 · Cited by 68
Burger, A. M., Hartung, G., Stehle, G., Sinn, H., & Fiebig, H. (2001) · International Journal of Cancer · Cited by 68
Dinarvand, R., Taheri, Rabbani, Khorramizadeh, M., Borougeni, A. T., Mansoori, & Atyabi, F. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s23949 · Cited by 66
Albumin-conjugated C34 Peptide HIV-1 Fusion Inhibitor
Stoddart, C. A., Nault, G., Galkina, S. A., Thibaudeau, K., Bakis, P., Bousquet-Gagnon, N., Robitaille, M., Bellomo, M., Paradis, V., Liscourt, P., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805536200 · Cited by 65
Cohen‐Barak, O., Wildeman, J., van de Wetering, J., Hettinga, J., Schuilenga‐Hut, P. H. L., Gross, A., Clark, S., Bassan, M., Gilgun‐Sherki, Y., Mendzelevski, B., et al. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.450 · Cited by 64
Shitara, K., Doi, T., Nagano, O., Fukutani, M., Hasegawa, H., Nomura, S., Sato, A., Kuwata, T., Asai, K., Einaga, Y., et al. (2017) · Gastric Cancer · doi:10.1007/s10120-017-0720-y · Cited by 63
Sun, Y., Zhao, Y., Teng, S., Hao, F., Zhang, H., Meng, F., Zhao, X., Zheng, X., Bi, Y., Yao, Y., et al. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s181296 · Cited by 63
Natural Brain Penetration Enhancer-Modified Albumin Nanoparticles for Glioma Targeting Delivery
Liang, J., Gao, C., Zhu, Y., Ling, C., Wang, Q., Huang, Y., Qin, J., Wang, J., Lu, W., & Wang, J. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b11782 · Cited by 62
Pedrozo, R. C., Antônio, E., Khalil, N. M., & Mainardes, R. M. (2020) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902019000317692 · Cited by 60
Maiti, T. K., Ghosh, K. S., Debnath, J., & Dasgupta, S. (2006) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2006.02.015 · Cited by 59
Taheri, A., Dinarvand, R., Atyabi, F., Ghahremani, M. H., & Ostad, S. N. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.06.016 · Cited by 59
Fiehn, C. (2004) · British journal of rheumatology · doi:10.1093/rheumatology/keh254 · Cited by 58
Enhanced tolerance and antitumor efficacy by docetaxel-loaded albumin nanoparticles
Tang, X., Wang, G., Shi, R., Jiang, K., Meng, L., Ren, H., Wu, J., & Hu, Y. (2015) · Drug Delivery · doi:10.3109/10717544.2015.1049720 · Cited by 55
Karami, K., Jamshidian, N., Hajiaghasi, A., & Amirghofran, Z. (2020) · New Journal of Chemistry · doi:10.1039/c9nj05847h · Cited by 54
Plant Polyphenols as Chemopreventive Agents
Nowak, R., Olech, M., & Nowacka-Jechalke, N. (2013) · Polyphenols in Human Health and Disease · doi:10.1016/b978-0-12-398456-2.00086-4 · Cited by 52
Paclitaxel loaded human serum albumin nanoparticles stabilized with intermolecular disulfide bonds
Zhao, S., Wang, W., Huang, Y., Fu, Y., & Cheng, Y. (2014) · MedChemComm · doi:10.1039/c4md00200h · Cited by 52
Shram, M. J., Cohen‐Barak, O., Chakraborty, B., Bassan, M., Schoedel, K. A., Hallak, H., Eyal, E., Weiss, S., Gilgun, Y., Sellers, E. M., et al. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000347 · Cited by 51
Taheri, A., Atyabi, F., Nouri, F. S., Ahadi, F., Derakhshan, M. A., Amini, M., Ghahremani, M. H., Ostad, S. N., Mansoori, P., & Dinarvand, R. (2010) · Journal of Nanomaterials · doi:10.1155/2011/768201 · Cited by 49
Sharma, A., Kaur, A., Jain, U. K., Chandra, R., & Madan, J. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.04.020 · Cited by 49
Abolhassani, H., & Shojaosadati, S. A. (2019) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2019.110534 · Cited by 48
Control ofIn VivoFate of Albumin Derivatives Utilizing Combined Chemical Modification
Fujita, T., Nishikawa, M., Ohtsubo, Y., Ohno, J., Takakura, Y., Sezaki, H., & Hashida, M. (1994) · Journal of drug targeting · doi:10.3109/10611869409015905 · Cited by 47
Taheri, A., Dinarvand, R., Atyabi, F., Ahadi, F., Nouri, F. S., Ghahremani, M., Ostad, S., Borougeni, A. T., & Mansoori, P. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12074591 · Cited by 46
Current multifunctional albumin-based nanoplatforms for cancer multi-mode therapy
Li, C., Wang, X., Song, H., Deng, S., Li, W., Li, J., & Sun, J. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2018.12.006 · Cited by 43
Preparation of albumin nanoparticles in water-in-ionic liquid microemulsions
Demirkurt, B., Cakan‐Akdogan, G., & Akdoğan, Y. (2019) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2019.111713 · Cited by 42
Fahrländer, E., Schelhaas, S., Jacobs, A. H., & Langer, K. (2015) · Nanotechnology · doi:10.1088/0957-4484/26/14/145103 · Cited by 41
Gilgun‐Sherki, Y., Eliaz, R. E., McCann, D. J., Loupe, P. S., Eyal, E., Blatt, K., Cohen‐Barak, O., Hallak, H., Chiang, N., & Gyaw, S. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.05.019 · Cited by 41
Golor, G., Bensen-Kennedy, D. M., Haffner, S. M., Easton, R., Jung, K., Moises, T., Lawo, J., Joch, C., & Veldman, A. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12409 · Cited by 40
Basto, A. P., Badenes, M., Almeida, S. C. P., Martins, C. L. V., Duarte, A., dos Santos, D. M. M. F., & Leitão, A. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.10.020 · Cited by 39
Characteristics of antibody responses induced in mice by protein allergens
Hilton, J., Dearman, R. J., Sattar, N., Basketter, D. A., & Kimber, I. (1997) · Food and Chemical Toxicology · doi:10.1016/s0278-6915(97)00119-1 · Cited by 38
Palmiero, U. C., Maraldi, M., Manfredini, N., & Moscatelli, D. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00127 · Cited by 38
Zollner, S., Schuermann, D., Raquet, E., Mueller‐Cohrs, J., Weimer, T., Pragst, I., Dickneite, G., & Schulte, S. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12477 · Cited by 34
Lv, L., Chi, Y., Chen, C., & Xu, W. (2013) · International Journal of Food Properties · doi:10.1080/10942912.2011.620204 · Cited by 34
Huang, H., Shi, H., Liu, J., Min, Y., Wang, Y., Wang, A. Z., Wang, J., & Liu, Y. (2017) · Chemical Communications · doi:10.1039/c6cc08146k · Cited by 34
Human Albumin Fragments Nanoparticles as PTX Carrier for Improved Anti-cancer Efficacy
Ge, L., You, X., Huang, J. C., Chen, Y., Chen, L., Zhu, Y., Zhang, Y., Liu, X., Wu, J., & Qian, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00582 · Cited by 34
A protein corona primer for physical chemists
Payne, C. K. (2019) · The Journal of Chemical Physics · doi:10.1063/1.5120178 · Cited by 34
Gharbavi, M., Danafar, H., & Sharafi, A. (2020) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36935 · Cited by 34
Curcumin-albumin conjugates as an effective anti-cancer agent with immunomodulatory properties
Aravind, S. R., & Krishnan, L. K. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.02.010 · Cited by 33
Gröschel, C., Sasse, A., Monecke, S., Röhrborn, C., Elsner, L., Didié, M., Reupke, V., Bunt, G., Lichtman, A. H., Toischer, K., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02665 · Cited by 31
Lei, J., Guan, B., Ли, Б., Duan, Z., Chen, Y., Li, H., & Jin, J. (2012) · Protein Expression and Purification · doi:10.1016/j.pep.2012.05.003 · Cited by 30
The use of CD47-modified biomaterials to mitigate the immune response
Tengood, J. E., Levy, R. J., & Stachelek, S. J. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216647130 · Cited by 30
Liu, Y., Yang, B., Zhao, X., Xi, M., & Yin, Z. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1403-2 · Cited by 30
Xiong, J., Han, S., Ding, S., He, J., & Zhang, H. (2018) · Oncology Reports · doi:10.3892/or.2018.6201 · Cited by 29
Enfuvirtide antiretroviral therapy in HIV-1 infection
Ramirez, C. M. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s1962 · Cited by 28
Chen, X., Wang, M., Hu, Y., Gong, T., Zhang, Z., Yu, R., & Fu, Y. S. (2020) · Journal of Materials Chemistry B · doi:10.1039/c9tb02780g · Cited by 27
Villaruz, L. C., & Socinski, M. A. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.022 · Cited by 25
Zhang, Z., Zhang, J., Jiang, M., Zhao, L., Li, S., Sun, H., Yang, F., & Liang, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00133 · Cited by 24
Zhou, C., Song, X., Guo, C., Tan, Y., Zhao, J., Yang, Q., Chen, D., Tan, T., Sun, X., Gong, T., et al. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b11307 · Cited by 23
Kovács, A. N., Varga, N., Gombár, G., Hornok, V., & Csapó, E. (2020) · Journal of Flow Chemistry · doi:10.1007/s41981-020-00088-4 · Cited by 20
Av, G., Shestak, N. V., Lavrova, N. V., et al. (2019) · Molecules · doi:10.3390/molecules24162892 · Cited by 18
Li, Z., Li, D., Zhang, W., Zhang, P., Kan, Q., & Sun, J. (2018) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2018.07.002 · Cited by 14
Dent, S. F., Fraser, J., Graham, N., Campbell, M., Hopkins, S. P., & Dranitsaris, G. (2013) · Current Oncology · doi:10.3747/co.20.1202 · Cited by 13
Novel Palladium Complex: Cytotoxicity against Cisplatin-resistant K562 Cells.
Jahanian‐Najafabadi, A., Mirian, M., Rohani, F., Karami, K., Kharat, M. H., & Sadeghi‐Aliabadi, H. (2019) · PubMed Central · doi:10.22037/ijpr.2019.1100714 · Cited by 12
Cited by
Polymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,155
Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets
Chen, R., Zhang, H., Tang, B., Luo, Y., Yang, Y., Zhong, X., Chen, S., Xu, X., Huang, S., & Liu, C. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01840-1 · Cited by 349
Desai, N., Rana, D., Patel, M., Bajwa, N., Prasad, R., & Vora, L. K. (2025) · Small · doi:10.1002/smll.202502315 · Cited by 295
Metadata
- Authors
- Spada, A., Emami, J., Tuszynski, J. A., & Lavasanifar, A.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-03-31
- Volume
- 18
- Issue
- 5
- Pages
- 1862-1894
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W3150503279
- Cited by
- 591
- References
- 170
- FWCI
- 18.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.